Bernd Doerken
Impact in
- Oncology top 1%
- Pancreatic and Hepatic Oncology Research
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
-
- Lymphoma Diagnosis and Treatment 9
-
- Lung Cancer Treatments and Mutations 7
- Co-authors
- Hanno Riess (3 shared papers)Helmut Oettle (2 shared papers)E. Kettner (1 shared paper)H Schramm (1 shared paper)Karsten Ridwelski (1 shared paper)Harald Schmalenberg (1 shared paper)Marco Niedergethmann (1 shared paper)Klaus Gellert (1 shared paper)
- Journals
- Blood (7 papers)BMC Cancer (2 papers)JAMA (1 paper)Journal of Clinical Oncology (1 paper)American Heart Journal (1 paper)
- Partner nations
- GermanySwitzerlandAustria
In The Last Decade
Bernd Doerken
18 papers receiving 2.1k citations
Bernd Doerken's Hit Papers
Peers
Comparison fields: 5 of 76
- Oncology 1.8k
- Cancer Research 509
- Pulmonary and Respiratory Medicine 672
- Epidemiology 661
- Surgery 729
Countries citing papers authored by Bernd Doerken
This map shows the geographic impact of Bernd Doerken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Doerken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Doerken more than expected).
Fields of papers citing papers by Bernd Doerken
This network shows the impact of papers produced by Bernd Doerken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Doerken. The network helps show where Bernd Doerken may publish in the future.
Co-authors
The 25 scholars most cited alongside Bernd Doerken, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer Hit paper breakdown → | 2007 | 1754 |
| 2 | 2001 | 115 | |
| 3 | 2010 | 58 | |
| 4 | 2015 | 41 | |
| 5 | 2009 | 36 | |
| 6 | 2005 | 34 | |
| 7 | 2008 | 23 | |
| 8 | 2005 | 17 | |
| 9 | 2005 | 15 | |
| 10 | 2012 | 10 | |
| 11 | 2009 | 9 | |
| 12 | 2004 | 9 | |
| 13 | 2004 | 8 | |
| 14 | 2009 | 6 | |
| 15 | 1991 | 5 | |
| 16 | I{kappa}B-{zeta} controls the constitutive NF-{kappa}B target gene network and survival of ABC DLBCL | 2013 | 4 |
| 17 | Monotherapy with the anti-CD20 antibody rituximab (ritux) in patients with post-transplant lympho-proliferative disease (PTLD). Results of a multicentre phase II study. | 2002 | 2 |
| 18 | Monoclonal antibodies against human thyroglobulin properties and their use in an immunoradiometric assay | 1986 | 2 |
| 19 | 2011 | 0 |
About Bernd Doerken
Bernd Doerken is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Epidemiology, Cancer Research and Hematology, having authored 19 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (9 papers), Lung Cancer Treatments and Mutations (7 papers), Multiple and Secondary Primary Cancers (4 papers), Acute Myeloid Leukemia Research (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Cancer Genomics and Diagnostics (2 papers), Chronic Myeloid Leukemia Treatments (2 papers) and MicroRNA in disease regulation (1 paper). The work is most often cited by research in Oncology (1.8k citations), Cancer Research (509 citations), Pulmonary and Respiratory Medicine (672 citations), Epidemiology (661 citations) and Surgery (729 citations). Bernd Doerken has collaborated with scholars based in Germany, Switzerland and Austria. Frequent co-authors include Hanno Riess, Helmut Oettle, E. Kettner, H Schramm, Karsten Ridwelski, Harald Schmalenberg, Marco Niedergethmann, Klaus Gellert, Jan M. Langrehr and Christof Burkart. Their work appears in journals such as Blood, BMC Cancer, JAMA, Journal of Clinical Oncology and American Heart Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.